Update on erectile dysfunction in prostate cancer patients

Current Opinion in Urology

Volumn 16, Issue 3, 2006, Pages 186-195

  Kendirci, Muammer ^a   Bejma, Jeffrey ^b   Hellstrom, Wayne J G ^b  

^a SISLI ETFAL TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Erectile dysfunction; Prostate cancer; Radical prostatectomy; Rehabilitation; Type 5 phosphodiesterase inhibitors

Indexed keywords

1 (3,3 DIMETHYL 1,2 DIOXOPENTYL) 2 PYRROLIDINECARBOXYLIC ACID 3 (3 PYRIDYL)PROPYL ESTER; ACIDIC FIBROBLAST GROWTH FACTOR; ANALGESIC AGENT; ANTIBIOTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; CARNITINE; GROWTH HORMONE; IMMUNOPHILIN; INO 1001; NERVE GROWTH FACTOR; NEUROTROPHIC FACTOR; NEURTRIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; PROSTAGLANDIN E1; PROTEIN DERIVATIVE; RECOMBINANT ERYTHROPOIETIN; SILDENAFIL; SOMATOMEDIN C; SONIC HEDGEHOG PROTEIN; TACROLIMUS; TADALAFIL; UNCLASSIFIED DRUG; VARDENAFIL; VASCULOTROPIN; VASOACTIVE AGENT;

AGING; BRACHYTHERAPY; CANCER EPIDEMIOLOGY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REHABILITATION; CANCER SURGERY; CLINICAL PROTOCOL; CLINICAL TRIAL; COMORBIDITY; CONVALESCENCE; CORPUS CAVERNOSUM; DEVICE; DISEASE SEVERITY; EPIDEMIOLOGICAL DATA; ERECTILE DYSFUNCTION; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; NERVE; NERVE GRAFT; NERVE INJURY; NERVE TRANSPLANTATION; NEUROPROTECTION; NEUROSURGERY; NONHUMAN; PATHOPHYSIOLOGY; PATIENT CARE; PENIS ERECTION; PENIS PROSTHESIS; PERIOPERATIVE PERIOD; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE SURGERY; PROSTATECTOMY; QUALITY OF LIFE; REVIEW; RISK FACTOR; SCHWANN CELL; SEXUAL FUNCTION; TREATMENT RESPONSE; VACUUM; VASCULAR DISEASE; VIRAL GENE THERAPY;

ANIMALS; COMBINED MODALITY THERAPY; FEMALE; IMPOTENCE; MALE; PENILE PROSTHESIS; PHOSPHODIESTERASE INHIBITORS; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RATS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 33646925910     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mou.0000193407.05285.d8     Document Type: Review

References (72)

1. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA 1993; 270:83-90.
2. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54:8-29.
3. Crawford ED, Bennett CL, Stone NN, et al. Comparison of perspectives on prostate cancer: analyses of survey data. Urology 1997; 50:366-372.
4. Penson DF, Feng Z, Kuniyuki A, et al. General quality of life 2 years following treatment for prostate cancer: what influences outcomes? Results from the prostate cancer outcomes study. J Clin Oncol 2003; 21:1147-1154.
5. Kendirci M, Hellstrom WJ. Current concepts in the management of erectile dysfunction in men with prostate cancer. Clin Prostate Cancer 2004; 3:87-92.
6. Hu JC, Elkin EP, Pasta DJ, et al. Predicting quality of life after radical prostatectomy: results from CaPSURE. J Urol 2004; 171:703-707 (discussion 707-708). This is a good study that evaluates sexual status of men following radical prostatectomy.
7. Stanford JL, Feng Z, Hamilton AS, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 2000; 283:354-360.
8. Penson DF, McLerran D, Feng Z, et al. 5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes study. J Urol 2005; 173:1701-1705. An excellent investigation that assesses temporal changes in sexual function for up to 5 years in men having undergone radical prostatectomy.
9. Steineck G, Helgesen F, Adolfsson J, et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002; 347:790-796.
10. Mulhall JP, Yonover P, Sethi A, et al. Radiation exposure to the corporeal bodies during 3-dimensional conformal radiation therapy for prostate cancer. J Urol 2002; 167:539-542.
11. Potosky AL, Legler J, Albertsen PC, et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst 2000; 92:1582-1592.
12. Litwin MS, Flanders SC, Pasta DJ, et al. Sexual function and bother after radical prostatectomy or radiation for prostate cancer: multivariate quality-of-life analysis from CaPSURE. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology 1999; 54:503-508.
13. Kury P, Stall G, Muller HW. Molecular mechanisms of cellular interactions in peripheral nerve regeneration. Curr Opin Neurol 2001; 14:635-639.
14. User HM, Hairston JH, Zelner DJ, et al. Penile weight and cell subtype specific changes in a post-radical prostatectomy model of erectile dysfunction. J Urol 2003; 169:1175-1179.
15. Moreland RB. Is there a role of hypoxemia in penile fibrosis: a viewpoint presented to the Society for the Study of Impotence. Int J Impot Res 1998; 10:113-120.
16. Leungwattanakij S, Bivalacqua TJ, Usta MF, et al. Cavernous neurotomy causes hypoxia and fibrosis in rat corpus cavernosum. J Androl 2003; 24:239-245.
17. Yao KS, Clayton M, O'Dwyer PJ. Apoptosis in human adenocarcinoma HT29 cells induced by exposure to hypoxia. J Natl Cancer Inst 1995; 87:117-122.
18. Klein LT, Miller Ml, Buttyan R, et al. Apoptosis in the rat penis after penile denervation. J Urol 1997; 158:626-630.
19. Yamanaka M, Shirai M, Shiina H, et al. Loss of anti-apoptotic genes in aging rat crura. J Urol 2002; 168:2296-2300.
20. Mulhall JP, Graydon RJ. The hemodynamics of erectile dysfunction following nerve-sparing radical retropubic prostatectomy. Int J Impot Res 1996; 8:91-94.
21. Mulhall JP, Slovick R, Hotaling J, et al. Erectile dysfunction after radical prostatectomy: hemodynamic profiles and their correlation with the recovery of erectile function. J Urol 2002; 167:1371-1375.
22. Iacono F, Giannella R, Somma P, et al. Histological alterations in cavernous tissue after radical prostatectomy. J Urol 2005; 173:1673-1676. This study presents good data on the deterioration of cavernosal histology following radical prostatectomy using penile biopsies.
23. Montorsi F, Guazzoni G, Strambi LF, et al. Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial. J Urol 1997; 158:1408-1410.
24. Fraiman MC, Lepor H, McCullough AR. Changes in penile morphometrics in men with erectile dysfunction after nerve-sparing radical retropubic prostatectomy. Mol Urol 1999; 3:109-115.
25. Savoie M, Kim SS, Soloway MS. A prospective study measuring penile length in men treated with radical prostatectomy for prostate cancer. J Urol 2003; 169:1462-1464.
26. Walsh PC. Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life: a structured debate. J Urol 2000; 163:1802-1807.
27. McCullough AR. Prevention and management of erectile dysfunction following radical prostatectomy. Urol Clin North Am 2001; 28:613-627.
28. Canada AL, Neese LE, Sui D, Schover LR. Pilot intervention to enhance sexual rehabilitation for couples after treatment for localized prostate carcinoma. Cancer 2005; 104:2689-2700. This is a good investigation that highlights the importance of counseling intervention in prostate cancer survivors and their partners.
29. Kendirci M, Hellstrom WJG. Restoring erectile function: proactive options after radical prostatectomy. Contemp Urol 2005; 17:36-50.
30. Walsh PC, Donker PJ. Impotence following radical prostatectomy: insight into etiology and prevention. J Urol 1982; 128:492-497.
31. Haffner MC, Landis PK, Saigal CS, et al. Health-related quality-of-life outcomes after anatomic retropubic radical prostatectomy in the phosphodiesterase type 5 ERA: impact of neurovascular bundle preservation. Urology 2005; 66:371-376. This article represents the impact of nerve preservation on longitudinal health-related quality-of-life outcomes after radical prostatectomy.
32. Lue TF, Gleason CA, Brock GB, et al. Intraoperative electrostimulation of the cavernous nerve: technique, results and limitations. J Urol 1995; 154:1426-1428.
33. Chang DW, Wood CG, Kroll SS, et al. Cavernous nerve reconstruction to preserve erectile function following non-nerve-sparing radical retropubic prostatectomy: a prospective study. Plast Reconstr Surg 2003; 111:1174-1181.
34. Kim ED, Nath R, Slawin KM, et al. Bilateral nerve grafting during radical retropubic prostatectomy: extended follow-up. Urology 2001; 58:983-987.
35. Quinlan DM, Nelson RJ, Walsh PC. Cavernous nerve grafts restore erectile function in denervated rats. J Urol 1991; 145:380-383.
36. Walsh PC. Nerve grafts are rarely necessary and are unlikely to improve sexual function in men undergoing anatomic radical prostatectomy. Urology 2001; 57:1020-1024.
37. Anastasiadis AG, Benson MC, Rosenwasser MP, et al. Cavernous nerve graft reconstruction during radical prostatectomy or radical cystectomy: safe and technically feasible. Prostate Cancer Prostatic Dis 2003; 6:56-60.
38. Walsh PC. Patient-reported urinary continence and sexual function after anatomic radical prostatectomy. J Urol 2000; 164:242.
39. Burnett AL. Rationale for cavernous nerve restorative therapy to preserve erectile function after radical prostatectomy. Urology 2003; 61:491-497.
40. Rabbani F, Stapleton AM, Kattan MW, et al. Factors predicting recovery of erections after radical prostatectomy. J Urol 2000; 164:1929-1934.
41. Padma-Nathan H, McCullough A, Giuliano F, et al. Postoperative nightly administration of sildenafil citrate significantly improved the return of normal spontaneous erectile function after bilateral nerve-sparing radical prostatectomy. J Urol 2003; 4:375.
42. Brock G, Tu LM, Linet OI. Return of spontaneous erection during long-term intracavernosal alprostadil (Caverject) treatment. Urology 2001; 57:536-541.
43. Montorsi F, Maga T, Strambi LF, et al. Sildenafil taken at bedtime significantly increases nocturnal erections: results of a placebo-controlled study. Urology 2000; 56:906-911.
44. Mulhall J, Land S, Parker M, et al. The use of an erectogenic pharmacotherapy regimen following radical prostatectomy improves recovery of spontaneous erectile function. J Sex Med 2005; 2:532-542. An excellent study that strengthens the importance of penile rehabilitation in men undergoing radical prostatectomy.
45. Gallo L, Perdona S, Autorino R, et al. Recovery of erection after pelvic urologic surgery: our experience. Int J Impot Res 2005; 17:484-493.
46. Davison BJ, Keyes M, Elliott S, et al. Preferences for sexual information resources in patients treated for early-stage prostate cancer with either radical prostatectomy or brachytherapy. BJU Int 2004; 93:965-969.
47. Moreland RB, Albadawi H, Bratton C, et al. O2-dependent prostanoid synthesis activates functional PGE receptors on corpus cavernosum smooth muscle. Am J Physiol Heart Circ Physiol 2001; 281:H552-H558.
48. Schwartz EJ, Wong P, Graydon RJ. Sildenafil preserves intracorporeal smooth muscle after radical retropubic prostatectomy. J Urol 2004; 171:771-774. Excellent data on the role of sildenafil on preservation of intracavernous smooth muscle.
49. Stephenson RA, Mori M, Hsieh YC, et al. Treatment of erectile dysfunction following therapy for clinically localized prostate cancer: patient reported use and outcomes from the Surveillance, Epidemiology, and End Results Prostate Cancer Outcomes Study. J Urol 2005; 174:646-650 (discussion 650). This is a good article that evaluates the importance of active surveillance and motivation of subjects for therapy of erectile dysfunction after prostate cancer treatment.
50. Zippe CD, Jhaveri FM, Klein EA, et al. Role of viagra after radical prostatectomy. Urology 2000; 55:241-245.
51. Zagaja GP, Mhoon DA, Aikens JE, Brendler CB. Sildenafil in the treatment of erectile dysfunction after radical prostatectomy. Urology 2000; 56:631-634.
52. Montorsi F, Salonia A, Zanoni M, et al. Current status of local penile therapy. Int J Impot Res 2002; 14 (Suppl 1):S70-S81.
53. Brock G, Nehra A, Lipshultz LI, et al. Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J Urol 2003; 170:1278-1283.
54. Nehra A, Grantmyre J, Nadel A, et al. Vardenafil improved patient satisfaction with erectile hardness, orgasmic function and sexual experience in men with erectile dysfunction following nerve sparing radical prostatectomy. J Urol 2005; 173:2067-2071.
55. Montorsi F, Verheyden B, Meuleman E, et al. Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction. Eur Urol 2004; 45:339-344 (discussion 344-335).
56. Raina R, Agarwal A, Ausmundson S, et al. Long-term efficacy and compliance of MUSE for erectile dysfunction following radical prostatectomy: SHIM (IIEF-5) analysis. Int J Impot Res 2005; 17:86-90.
57. Raina R, Lakin MM, Agarwal A, et al. Long-term effect of sildenafil citrate on erectile dysfunction after radical prostatectomy: 3-year follow-up. Urology 2003; 62:110-115.
58. Nehra A, Blute ML, Barrett DM, Moreland RB. Rationale for combination therapy of intraurethral prostaglandin E(1) and sildenafil in the salvage of erectile dysfunction patients desiring noninvasive therapy. Int J Impot Res 2002; 14 (Suppl 1):S38-S42.
59. Raina R, Nandipati KC, Agarwal A, et al. Combination therapy: medicated urethral system for erection enhances sexual satisfaction in sildenafil citrate failure following nerve-sparing radical prostatectomy. J Androl 2005; 26:757-760.
60. Gontero P, Fontana F, Zitella A, et al. A prospective evaluation of efficacy and compliance with a multistep treatment approach for erectile dysfunction in patients after non-nerve sparing radical prostatectomy. BJU Int 2005; 95:359-365. This study outlines a multistep treatment approach in men following radical prostatectomy.
61. Raina R, Agarwal A, Allamaneni SS, et al. Sildenafil citrate and vacuum constriction device combination enhances sexual satisfaction in erectile dysfunction after radical prostatectomy. Urology 2005; 65:360-364.
62. Gontero P, Fontana F, Bagnasacco A, et al. Is there an optimal time for intracavernous prostaglandin E1 rehabilitation following nonnerve sparing radical prostatectomy? Results from a hemodynamic prospective study. J Urol 2003; 169:2166-2169.
63. Raina R, Lakin MM, Agarwal A, et al. Long-term intracavernous therapy responders can potentially switch to sildenafil citrate after radical prostatectomy. Urology 2004; 63:532-537 (discussion 538).
64. Mydlo JH, Viterbo R, Crispen P. Use of combined intracorporal injection and a phosphodiesterase-5 inhibitor therapy for men with a suboptimal response to sildenafil and/or vardenafil monotherapy after radical retropubic prostatectomy. BJU Int 2005; 95:843-846.
65. Cavallini G, Modenini F, Vitali G, Koverech A. Acetyl-L-carnitine plus propionyl-L-carnitine improve efficacy of sildenafil in treatment of erectile dysfunction after bilateral nerve-sparing radical retropubic prostatectomy. Urology 2005; 66:1080-1085.
66. Khoudary KP, DeWolf WC, Bruning CO 3rd, Morgentaler A. Immediate sexual rehabilitation by simultaneous placement of penile prosthesis in patients undergoing radical prostatectomy: initial results in 50 patients. Urology 1997; 50:395-399.
67. Ramsawh HJ, Morgentaler A, Covino N, et al. Quality of life following simultaneous placement of penile prosthesis with radical prostatectomy. J Urol 2005; 174:1395-1398. This is a good study that shows the feasibility of simultaneous penile prosthetic implantation during radical prostatectomy.
68. Sezen SF, Hoke A, Burnett AL, Snyder SH. Immunophilin ligand FK506 is neuroprotective for penile innervation. Nat Med 2001; 7:1073-1074.
69. Burnett AL. Neuroprotection and nerve grafts in the treatment of neurogenic erectile dysfunction. J Urol 2003; 170:331-834 (discussion S34).
70. Kendirci M, Zsengeller Z, Bivalacqua TJ, et al. Poly(Adenosine diphosphate-ribose) polymerase inhibition preserves erectile function in rats after cavernous nerve injury. J Urol 2005; 174:2054-2059. This animal study demonstrates the involvement of PARP in cavernous nerve injury and the therapeutic benefit of the PARP inhibitors on cavernous neuroprotection.
71. Allaf ME, Hoke A, Burnett AL. Erythropoietin promotes the recovery of erectile function following cavernous nerve injury. J Urol 2005; 174:2060-2064. This study in the rat shows the benefit of exogenous administration of rhEPO on the regeneration of the cavernous nerve and the recovery of erectile function following injury.
72. May F, Weidner N, Matiasek K, et al. Schwann cell seeded guidance tubes restore erectile function after ablation of cavernous nerves in rats. J Urol 2004; 172:374-377.